Maheedhar Gedela, MD
Interventional Cardiology · Wichita, KSNPI 1104231216
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.6%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Medtronic at 53.6% of the total. Among interventional cardiology clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 600 payments — averaging $90.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$29K
- Abbott$9K
- Edwards Lifesciences$4K
- Abiomed$2K
- Philips North America LLC$2K
- Boston Scientific$1K
- plus $8K from 29 others
What the payments were for
- Speaking & faculty fees$6,35012%
- Grants$11,14021%
- Travel & lodging$14,75027%
- Food & beverage$20,96339%
- Education$1,0232%
- Gifts$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 105 | $29,087 |
| Abbott | 128 | $8,595 |
| Edwards Lifesciences | 28 | $3,505 |
| Abiomed | 19 | $1,996 |
| Philips North America LLC | 15 | $1,850 |
| Boston Scientific | 26 | $1,181 |
| Cardiovascular Systems Inc. | 34 | $1,082 |
| Shockwave Medical, Inc | 27 | $948 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 40 | $680 |
| Amgen | 26 | $672 |
| AstraZeneca | 17 | $553 |
| Chiesi USA, Inc. | 23 | $551 |
| Siemens Medical Solutions USA, Inc. | 2 | $522 |
| E.r. Squibb & Sons, L.L.C. | 26 | $432 |
| Terumo Medical Corporation | 17 | $424 |
| Pfizer | 17 | $408 |
| Biotronik Inc. | 10 | $351 |
| Johnson & Johnson | 7 | $260 |
| Astellas Pharma US Inc | 2 | $190 |
| Acist Medical Systems, Inc. | 2 | $165 |
| Cordis US CORP. | 4 | $133 |
| Biosense Webster, Inc. | 1 | $120 |
| Novartis | 6 | $98 |
| Cardiva Medical, Inc. | 3 | $91 |
| Teleflex LLC | 4 | $90 |
| Heartflow, Inc. | 1 | $57 |
| Asahi Intecc USA, Inc. | 2 | $50 |
| Penumbra, Inc. | 1 | $49 |
| Getinge USA Sales, LLC | 1 | $38 |
| Cardinal Health 200 LLC | 1 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| W. L. Gore & Associates, Inc. | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $17 |
| Cardiofocus, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$11,169
- CoreValve Evolut$11,140
- Micra$2,089
- MitraClip$1,558
- TRICLIP$1,392
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,362
- (9525) Intracardiac Und$1,334
- Resolute$1,288
- Impella$1,140
- Xience V coronary stent system$1,032
- Xience Sierra Coronary Stent System$292
- Supera peripheral stent system$270
- SUPERA$173
- Orsiro$169
- Astron; Pulsar; AstronPulsar$169
- PRO-Kinetic Energy$169
- Pulsar$169
- PK Papyrus$169
- WAINUA$161
- (AO0) IGT Devices Intracardiac$156
How this compares
$54,301 in reported general payments places this provider in the 95th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 267 | $220,286 |
| EntrestoSacubitril/Valsartan | 56 | $50,678 |
| FarxigaDapagliflozin Propanediol | 76 | $50,201 |
| JardianceEmpagliflozin | 36 | $39,565 |
| XareltoRivaroxaban | 35 | $38,854 |
| Praluent PenAlirocumab | 20 | $12,875 |
| BrilintaTicagrelor | 18 | $7,655 |
| Bumetanide | 159 | $4,785 |
| Potassium Chloride | 147 | $2,632 |
| ClopidogrelClopidogrel Bisulfate | 308 | $1,950 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 46 | $1,809 |
| Ranolazine ErRanolazine | 15 | $1,709 |
| Metoprolol Succinate | 217 | $1,569 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 20 | $1,196 |
| Amlodipine Besylate | 231 | $983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $408 | $220,286267 claims |
| AstraZenecaFarxiga, Brilinta | $553 | $57,85694 claims |
| NovartisEntresto | $98 | $50,67856 claims |
| Johnson & JohnsonXarelto | $260 | $38,85435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Wichita
- Hussam FarhoudWichita$25K
- Christian HouraniWichita$17K
- Gaurav TyagiWichita$13K
- Ravi BajajWichita$10K
- Assem FarhatWichita$9K
- Venkata BoppanaWichita$9K
- Alaa BouladWichita$8K
- Rohma ShaikhWichita$4K
- George ReaderWichita$4K
- Mohamed ElmassryWichita$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.